Feature Profound Medical readies pivotal clinical trial of TULSA-PRO By Len Zehr After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX... May 3, 2016